pentadecapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection of dry material |
| Solubility | Soluble in water | Polar aqueous solvent class |
| Typical storage | Minus 20 degrees Celsius, desiccated, dark | Applies to the lyophilized form |
| Purity assessment | Reversed-phase HPLC | Ultraviolet detection, area percent |
| Identity confirmation | Mass spectrometry | Measured mass compared with theoretical value |
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
== Expression == In humans, GHBP is formed by post-translational modification after the complete transcription and translation of the growth hormone receptor (GHR) gene into the cell-surface receptor protein. The gene that codes for GHR (and inherently GHBP) is on Chromosome 5. A precursor messenger RNA (mRNA) from the complete gene first is transcribed and then spliced to encode the full receptor protein. This mature mRNA is composed of exons. Exons are peptide encoding regions of DNA genes that remain in the transcript after splicing and during the maturation of mRNA. The mRNA transcript encodes for a receptor protein that is made up of three distinct parts: an intracellular domain, a transmembrane domain, and an extracellular domain. Specifically, part of exon 2 and exons 3-7 of the GHR gene will translate to amino acids that make up the extracellular domain of GHR. This extracellular domain physically binds GH in the receptor-ligand interaction.
Benzoic acid derivatives The benzoyl derivative cellotropin has been used for tuberculosis. Populin, which occurs in the leaves and bark of Populus tremula, is benzoyl salicin. Benzoyl-beta-D-glucoside is a compound found in the fern Pteris ensiformis.
The most common molecule in the Universe, H2 (molecular hydrogen), is completely invisible to radio telescopes because it has no dipole; its electronic transitions are too energetic for optical telescopes, so detection of H2 required ultraviolet observations with a sounding rocket. Vibrational lines are often not specific to an individual molecule, allowing only the general class to be identified. For example, the vibrational lines of polycyclic aromatic hydrocarbons (PAHs) were identified in 1984, showing the class of molecules is very common in space, but it took until 2021 to identify any specific PAHs through their rotational lines.
Sources: en.wikipedia.org
Currently the Orbitrap analyzer exists in two variants: a standard trap and a compact high-field trap. In practical traps, the outer electrode is sustained at virtual ground and a voltage of 3.5 or 5 kV is applied to the inner electrode only. As a result, the resolving power at m/z 400 and 768 ms detection time can range from 60,000 for a standard trap at 3.5 kV to 280,000 for a high-field trap at 5 kV and with enhanced FT processing. Like in FTICR-MS the Orbitrap resolving power is proportional to the number of harmonic oscillations of the ions; as a result, the resolving power is inversely proportional to the square root of m/z and proportional to acquisition time. For example, the values above would double for m/z 100 and halve for m/z 1600. For the shortest transient of 96 ms these values would be reduced by 8 times, whereas a resolving power in excess of 1,000,000 has been demonstrated in 3-second transients. The Orbitrap analyzer can be interfaced to a linear ion trap (LTQ Orbitrap family of instruments), quadrupole mass filter (Q Exactive family) or directly to an ion source (Exactive instrument, all marketed by Thermo Fisher Scientific). In addition, a higher-energy collision cell can be appended to the C-trap, with the further addition of electron-transfer dissociation at its back. Most of these instruments have atmospheric pressure ion sources though an intermediate-pressure MALDI source can also be used (MALDI LTQ Orbitrap).
Narrated by Miriam Margolyes, directed by Karl Sabbagh, made by Skyscraper Productions with KCTS 5 October The Mystery of Anastasia, an Equinox Special, about Anna Anderson; the Romanovs were murdered in Siberia on 17 July 1918; the Forensic Science Service at Aldermaston; forensic scientist William R. Maples; Peter Kurth; David Ellen, of Scotland Yard; Gleb Botkin; Peter Vanezis, Regius Professor of Forensic Medicine (Glasgow) and ears; former Danish ambassador to Germany Herluf Zahle; Ernest Louis, Grand Duke of Hesse hired detective Martin Knopf, who found Anna Anderson's possible name; Geoff Oxley, and facial recognition computing looking at Frances; Patrick Lincoln of London Hospital Medical College, and heredity of blood groups, and the A2 blood group; Peter French, who researched pronunciation; pathologist Hunt MacMillan III and Peter Gill of the Forensic Science Service (Birmingham); in Charlottesville in June 1994; David Enoch (psychiatrist) of the Royal Liverpool University Hospital; the Duke of Edinburgh provided a blood sample to prove mitochondrial DNA, as he was related to Anastasia; Prince Rostislav Rostislavovich Romanov (1938-1999), father of Prince Rostislav Romanov (born 1985); Kevin Sullivan of the Forensic Service; Anna Anderson was not Anastasia, according to mitochondrial DNA of the Duke of Edinburgh.
Wounded healer is a term created by psychiatrist Carl Jung. The idea states that an analyst is compelled to treat patients because the analyst himself is "wounded." The idea may have Greek mythology origins. Victor et al. (2022) found that 82% of applied psychology graduate students and faculty members in the United States and Canada experienced mental health conditions at some point in their lives. As an example, of the "wounded healer phenomenon" between an analyst and their analyzed:
Sources: en.wikipedia.org
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.
Mass spectrometry establishes the molecular mass, and reversed-phase chromatography reports purity. A certificate of analysis typically combines both results.
Solutions degrade faster than the dry powder, particularly at room temperature. Portioning into single-use aliquots and freezing reduces losses from repeated thawing.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.